Compare Gilead Sciences, Inc. (GILD) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Corning Incorporated — how do they compare? Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B), while Corning Incorporated trades at $157.36 (market cap $131.65B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Corning Incorporated for 35 Days on average.
| GILD | GLW | |
|---|---|---|
Market Cap | $182.40B | $131.65B |
Volume | 4,469,821 | 8,992,522 |
Sector | Health | Technology |
52-Week High | $155.80 | $255.79 |
52-Week Low | $116.74 | $78.03 |
Typical Hold Time | 111 Days | 35 Days |
Enterprise Value | $205.46B | $138.52B |
Dividend Yield | 2.23% | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
GLW trades at $163.21, down 3.41% today, with a bullish technical signal and strong analyst support (56.75% buy ratings). Recent fundamentals show robust revenue growth to $15.63B in 2025 and net income of $1.60B, though valuation ratios like P/E of 70.43 appear elevated. The company secured a significant $3B+ fiber supply deal with AT&T, driving positive sentiment amid AI infrastructure demand.
Outlook is positive with earnings beats and a consensus price target of $171.25 offering ~5% upside. Key risks include high debt levels, patent litigation, and sensitivity to tech spending cycles. Institutional confidence remains high given operational cash flow strength and strategic positioning in fiber optics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
